Beam Therapeutics' Q4 Earnings & Revenues Beat Estimates

Financial Performance - Beam Therapeutics reported a loss of $1.09 per share for Q4 2024, which was narrower than the Zacks Consensus Estimate of a loss of $1.10, compared to earnings of $1.73 per share in the same quarter last year [1] - Total revenues for Q4 2024 were $30.1 million, significantly lower than $316.2 million in the year-ago period, but exceeded the Zacks Consensus Estimate of $21 million [2] - For the full year 2024, revenues were $63.5 million, down from $377.7 million in the previous year, with an adjusted loss of $4.58 per share, wider than a loss of $1.72 per share reported in the prior year [4] Expense Management - Research and development expenses in Q4 2024 were $101.4 million, down nearly 27.6% from the previous year [3] - General and administrative expenses totaled $28.7 million, decreasing around 33.7% year over year [3] Cash Position - As of December 31, 2024, Beam Therapeutics had cash, cash equivalents, and marketable securities worth $850.7 million, down from $925.8 million as of September 30, 2024, with expectations to fund operating expenses into 2027 [3] Pipeline Developments - The company is advancing its leading ex-vivo genome-editing candidate, BEAM-101, in the phase I/II BEACON study for treating adult patients with sickle cell disease, with new safety and efficacy data announced in December 2024 [7] - Treatment with BEAM-101 showed a robust and durable increase in fetal hemoglobin and a reduction in sickle hemoglobin, along with rapid neutrophil and platelet engraftment [8] - Beam Therapeutics is also expanding its pipeline with BEAM-301 and BEAM-302 for glycogen storage disease type 1a and alpha-1 antitrypsin deficiency, respectively, with patient dosing for BEAM-301 expected to begin shortly [9] Market Performance - Over the past year, shares of Beam Therapeutics have declined by 33.8%, while the industry has seen a decline of 9.7% [2]